Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

M. Khanani, Arshad; Patel, Sunil; J. Ferrone, Philip; Osborne, Aaron; Sahni, Jayashree; M. Grzeschik, Susanna; Basu, Karen; S. Ehrlich, Jason; Hašková, Zdenka; U. Dugel, Pravin

doi:10.1001/jamaophthalmol.2020.2699

Public

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration

Published in JAMA Ophthalmology • Jul 30, 2020

Authors:

Arshad M. Khanani

Sunil Patel

Philip J. Ferrone

Abstract

Importance: Faricimab neutralizes angiopoietin-2 and vascular endothelial growth factor A via both simultaneous and independent binding. Objective: To evaluate extended dosing with faricimab, the first bispecific antibody designed for intraocular use, in patients with neovascular age-related macular...

Subject

Medicine

Macular degeneration

Choroidal neovascularization

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!